European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme

Annals of Oncology

Volumn 14, Issue 12, 2003, Pages 1732-1734

  van den Bent, M J ^a   Grisold, W ^b   Frappaz, D ^c   Stupp, R ^d   Desir, J P ^e   Lesimple, T ^f   Dittrich, C ^b   de Jonge, M J A ^a   Brandes, A ^g   Frenay, M ^h   Carpentier, A F ⁱ   Chollet, P ^j   Oliveira, J ^k   Baron, B ^l   Lacombe, D ^l   Schuessler, M ^m   Fumoleau, P ⁿ  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c CENTRE LÉON BÉRARD   (France)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f CENTRE EUGÈNE MARQUIS   (France)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h Centre Lacassagne   (France)

ⁱ Section of Radiology   (France)

^j CENTRE JEAN PERRIN   (France)

^k INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^l EORTC DATA CENTER   (Belgium)

^m Baxter Oncology GmbH   (Germany)

ⁿ CENTRE RENÉ GAUDUCHEAU   (France)

more..

Author keywords

Chemotherapy; Glioblastoma multiforme; Glufosfamide; Recurrent

Indexed keywords

ALKYLATING AGENT; ANTICONVULSIVE AGENT; BILIRUBIN; CARBAMAZEPINE; CREATININE; ENZYME INDUCING AGENT; GLUFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRAIN SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG RESPONSE; ELECTROLYTE DISTURBANCE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RADIOTHERAPY; SURVIVAL TIME; TUMOR GROWTH; TUMOR RECURRENCE; VOMITING;

EID: 9144219841     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg491     Document Type: Article

References (13)

1. Yung WKA, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
2. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2000; 12: 259-266.
3. +-D-glucose cotransporter SAAT1. Proc Natl Acad Sci USA 1998; 95: 2914-2919.
4. Depenbrock H, Dumez H, van Oosterom AT et al. Phase I clinical and pharmacokinetic study of glufosfamide administered as a short time infusion every three weeks in patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 118a (Abstr 468).
5. Briasoulis E, Judson I, Pavlidis N et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization of Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 2000; 18: 3535-3444.
6. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
7. Yung WKA, Prados M, Yaya-Tur R et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999; 17: 2762-2771.
8. Fleming TR. One-sample multiple testing procedures for phase II clinical trials. Biometrics 1982; 38: 143-151.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Star Assoc 1958; 53: 457-481.
10. Walker RW, Cairncross JG, Posner JB. Cerebral herniation in patients receiving cisplatin. J Neuro-Oncol 1988; 6: 61-65.
11. Chang SM, Kuhn JG, Rizzo J et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol 1998; 16: 2188-2194.
12. Friedman HS, Petros WP, Friedman A et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 1999; 17: 1516-1525.
13. Osoba D, Brada M, Yung WKA, Prados MD. Health related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000; 36: 1788-1795.